Anti-Dabigatran Etexilate Mesylate Reference Antibody (Idarucizumab, RUO) (YP598016)

Name: Anti-Dabigatran Etexilate Mesylate Reference Antibody (Idarucizumab, RUO)
Brand: abinScience
SKU: YP598016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

YP598016

Descripción

Idarucizumab (YP598016) is a research-grade recombinant antibody targeting Dabigatran Etexilate Mesylate. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactividad de especies

General

Aplicaciones

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Especie huésped

Human

Clonalidad

Monoclonal

Isotipo

Fab-G1-kappa

Sistema de expresión

Mammalian cells

Objetivo

Dabigatran Etexilate Mesylate

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% purity as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

CAS: 211915-06-9

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Nombres alternativos

aDabi-Fab, anti-dabigatran, antidotefordabigatran, CAS: 1362509-93-0

Fondo

Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
• Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737
• Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915
• The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200
• Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994
• A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461
• Idarucizumab for Dabigatran Reversal - Full Cohort Analysis., PMID:28693366
• Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082
• Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499
• Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346
• The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158

Nota

For research use only. Not suitable for clinical or therapeutic use.

Isotype Control

Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

Imágenes

SDS-PAGE

SDS-PAGE for Research Grade Idarucizumab

Referencias

Datasheet

Anti-Dabigatran Etexilate Mesylate Reference Antibody (Idarucizumab, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Proteínas Recombinantes

Anticuerpos

Kits de Ensayo